PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 135 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $892,820 | -16.0% | 81,835 | -35.1% | 0.14% | -9.9% |
| Q3 2022 | $1,063,000 | +51.6% | 126,038 | +42.3% | 0.16% | +159.7% |
| Q2 2022 | $701,000 | +85.4% | 88,578 | +454.7% | 0.06% | +87.9% |
| Q1 2022 | $378,000 | -31.0% | 15,968 | -0.3% | 0.03% | -21.4% |
| Q4 2021 | $548,000 | +4.2% | 16,018 | -46.1% | 0.04% | +10.5% |
| Q3 2021 | $526,000 | +136.9% | 29,700 | -5.5% | 0.04% | +111.1% |
| Q1 2020 | $222,000 | -27.5% | 31,421 | -27.6% | 0.02% | -5.3% |
| Q4 2019 | $306,000 | +29.7% | 43,406 | +121.2% | 0.02% | +35.7% |
| Q3 2019 | $236,000 | +29.7% | 19,621 | +30.7% | 0.01% | +27.3% |
| Q2 2019 | $182,000 | -71.1% | 15,011 | -50.4% | 0.01% | -38.9% |
| Q4 2017 | $630,000 | +37.6% | 30,266 | +16.9% | 0.02% | +20.0% |
| Q3 2017 | $458,000 | +132.5% | 25,900 | +48.9% | 0.02% | +87.5% |
| Q2 2017 | $197,000 | -14.7% | 17,400 | -3.3% | 0.01% | -33.3% |
| Q1 2017 | $231,000 | – | 18,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |